Mepartricin

Mepartricin

Systematic (IUPAC) name
(19E,21E,23Z,25Z,27E,29E,31E)-methyl 34-((2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-1,3,5,7,9,13,37-heptahydroxy-17-(5-hydroxy-7-[4-(methylamino)phenyl]-7-oxoheptan-2-yl)-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate
Clinical data
AHFS/Drugs.com	International Drug Names
Identifiers
CAS Number	62534-68-3 Y
ATC code	A01AB16 (WHO) D01AA06 G01AA09 G04CX03
PubChem	CID: 6479653
ChemSpider	21106342 Y
ChEMBL	CHEMBL2106426
Chemical data
Formula	C60H88N2O19
Molecular mass	1141.34 g/mol
SMILES CNc1ccc(cc1)C(=O)CC(O)CCC(C)C3OC(=O)CC(O)CC(=O)CC(O)CC(O)CC(O)CC(O)CC4(O)CC(O)C(C(=O)OC)C(CC(O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)/C=C/C=C/C=C/C=C\C=C/C=C/C=C/C3C)O4
InChI InChI=1S/C60H88N2O19/c1-36-18-16-14-12-10-8-6-7-9-11-13-15-17-19-48(79-59-56(74)54(61)55(73)38(3)78-59)33-51-53(58(75)77-5)50(71)35-60(76,81-51)34-47(69)30-45(67)28-43(65)26-42(64)27-44(66)29-46(68)32-52(72)80-57(36)37(2)20-25-41(63)31-49(70)39-21-23-40(62-4)24-22-39/h6-19,21-24,36-38,41-43,45-48,50-51,53-57,59,62-65,67-69,71,73-74,76H,20,25-35,61H2,1-5H3/b7-6-,10-8-,11-9+,14-12+,15-13+,18-16+,19-17+/t36?,37?,38-,41?,42?,43?,45?,46?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59+,60?/m1/s1 Y Key:GVEVTKSEPQUIJA-PLDHRHJXSA-N Y
(verify)

Mepartricin is an macrolide polyene compound that is useful for urethra, prostate and bladder function. It has been studied for use in treating chronic pelvic pain syndrome and benign prostatic hyperplasia.

Pharmacodynamics

Mepartricin is estrogen reabsorption inhibitor that may interfere with the reabsorption of estrogens in the gut leading to increased fecal estrogen excretion. It reduces 17 β estradiol concentration in enterohepatic circulation and decreases estrogen levels in the prostate. The effect of mepartricin on the reabsorption of estrogens was evaluated in studies in vitro and in vivo.

Mepartricin significantly improves pelvic pain and quality of life compared with the results in placebo group after two months of treatment. Regarding to the theory that hormonal disorders could promote prostatic inflammation, mepartricin, that can lower estrogen levels in prostate, is effective drug in the treatment of patients with chronic pelvic pain syndrome and is referred in 2015 World Journal Pharmacology Updates on therapies for chronic prostatitis/chronic pelvic pain syndrome.